GlucoTrack

GlucoTrack ROA

The Return on Assets (ROA) of GlucoTrack (GCTK) as of Oct 23, 2026 is -247.36 %. In the previous year, Return on Assets (ROA) was -380.93 % — a change of -35.07% (higher).

ROA

-247.36 %

YoY

-35.07%

Last updated:

In 2025, GlucoTrack's return on assets (ROA) was -247.36 %, a -35.07% increase from the -380.93 % ROA in the previous year.

The GlucoTrack ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-975.81 USD
Jan 1, 2019
-320.80 USD
Jan 1, 2020
-25.42 USD
Jan 1, 2021
-64.92 USD
Jan 1, 2022
-181.91 USD
Jan 1, 2023
-144.69 USD
Jan 1, 2024
-380.93 USD
Jan 1, 2025
-247.36 USD
The GlucoTrack ROA history
YEARROAYoY
-247.36 %-35.07%
-380.93 %+163.28%
-144.69 %-20.46%
-181.91 %+180.22%
-64.92 %+155.38%
-25.42 %-92.08%
-320.80 %-67.12%
-975.81 %+57.67%
-618.89 %+181.54%
-219.82 %-19.75%
-273.94 %-683.48%
46.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlucoTrack Stock analysis

What does GlucoTrack do? GlucoTrack, Inc. makes money by selling non-invasive glucose monitoring devices and related software solutions to people with diabetes and pre-diabetes. The company's GlucoTrack device provides glucose level readings without finger sticks, targeting Type II diabetes and prediabetes users. It also develops an implantable continuous glucose monitor for Type I diabetes and insulin-dependent Type II diabetes patients. The firm offers companion applications and cloud-based solutions to deliver real-time, data-driven tools for diabetes management. Its primary customers are individuals managing diabetes through non-invasive monitoring solutions, with a focus on Type II diabetes and pre-diabetes segments. GlucoTrack, Inc. generates revenue through the commercialization of its non-invasive glucose monitor and the development of its implantable continuous glucose monitor. The company's products are designed for specific diabetes segments: Type II diabetes and prediabetes users for the GlucoTrack device, and Type I diabetes and insulin-dependent Type II diabetes patients for the implantable monitor. The firm's cloud-based platform and companion apps are integral to its service offering, providing personalized diabetes management tools. Revenue streams include device sales and software services for these targeted user groups. The company's business model centers on direct sales of its GlucoTrack device and implantable monitor to diabetes patients. It focuses on Type II diabetes and prediabetes for the non-invasive monitor, while the implantable version targets Type I diabetes and insulin-dependent Type II diabetes. The firm's cloud-based solutions and companion applications are sold as part of the overall diabetes management platform. Revenue is derived from both hardware sales and subscription-based software services for these specific patient segments. GlucoTrack is one of the most popular companies on Eulerpool.

ROA Details

Understanding GlucoTrack's Return on Assets (ROA)

GlucoTrack's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing GlucoTrack's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider GlucoTrack's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in GlucoTrack’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about GlucoTrack stock

Return on Assets (ROA) of GlucoTrack is -247.36 % in 2025.

Return on Assets (ROA) of GlucoTrack changed from -380.93 % to -247.36 %, representing a -35.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) GlucoTrack since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s GlucoTrack with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GlucoTrack

All Key Metrics — GlucoTrack